Drug Profile
Naloxone intranasal spray - Hikma Pharmaceuticals
Alternative Names: KLOXXADO; Naloxone hydrochloride nasal spray - Hikma Pharmaceuticals; Naloxone nasal spray - Hikma PharmaceuticalsLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Hikma Pharmaceuticals
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
Most Recent Events
- 20 Nov 2023 Hikma Pharmaceuticals has patent protection for "Liquid naloxone spray" in USA
- 14 Jun 2023 Hikma Pharmaceuticals initiates litigation against Padagis over ANDA submission in USA
- 09 Aug 2021 Launched for Opioid-related disorders (In adolescents, In children, In adults) in USA (Intranasal)